All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Does the VenDd +/- bortezomib combination represent a new treatment option for patients with RRMM?
Featured:
Nizar BahlisThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Nizar Bahlis, University of Calgary, Calgary, CA, answers the question: Does the combination of venetoclax, daratumumab, dexamethasone, with or without bortezomib, represent a new treatment option for patients with relapsed/refractory myeloma?
Nizar Bahlis talk about the M1564 trial that looks at daratumumab combined with venetoclax, with or without bortezomib in patients with relapsed multiple myeloma. He discussed the potential of bortezomib being able to sensitize patients to the effect of venetoclax treatment. He explains the overall response rates of patients in this study
Does the VenDd +/- bortezomib combination represent a new treatment option for patients with RRMM?
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?